Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Acquisition Narrative (Details)

v3.6.0.2
Acquisitions, Investments, and Licenses - Acquisition Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 5 Months Ended 8 Months Ended 12 Months Ended
Aug. 31, 2016
Aug. 31, 2015
May 31, 2015
Sep. 30, 2016
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Business Acquisition [Line Items]                                  
Net income (loss)                             $ (25,083) $ (30,028) $ (171,666)
Measurement period adjustment, goodwill                             (35,884) 524,531  
Tax benefit                             56,115 113,675 (24)
Goodwill         $ 704,603       $ 743,348       $ 743,348 $ 743,348 704,603 743,348 224,292
Revenues         275,489 $ 298,035 $ 357,100 $ 291,037 $ 276,191 $ 143,034 $ 42,429 $ 30,084     1,221,661 $ 491,738 $ 91,125
Common Stock                                  
Business Acquisition [Line Items]                                  
Stock price (in dollars per share) $ 9.10 $ 12.38 $ 13.88                            
Transition Therapeutics, Inc.                                  
Business Acquisition [Line Items]                                  
Total purchase price $ 58,500                                
Revenues       $ 0                          
Net income (loss)       $ (2,600)                          
Goodwill $ 3,453                                
Transition Therapeutics, Inc. | Common Stock                                  
Business Acquisition [Line Items]                                  
Common stock received, in shares (in shares) 6,431,899                                
Bio-Reference Laboratories, Inc.                                  
Business Acquisition [Line Items]                                  
Total purchase price   $ 950,148                              
Net income (loss)                         3,200        
Value of replacement stock options awards to holders of Bio-Reference stock options   2,259                              
Measurement period adjustment, other current assets                             44,600    
Measurement period adjustment, goodwill                             (39,300)    
Measurement period adjustment, accrued expenses                             (500)    
Measurement period adjustment, income taxes payable                             2,500    
Measurement period adjustment, deferred tax liability                             (600)    
Measurement period adjustment, noncurrent liabilities, other                             6,300    
Increase in amortization of intangible assets                             3,100    
Goodwill   $ 401,821     401,821                   $ 401,821    
Revenues                         $ 321,900        
Useful life   13 years                              
Bio-Reference Laboratories, Inc. | Common Stock                                  
Business Acquisition [Line Items]                                  
Common stock received, in shares (in shares)   76,566,147                              
Acquired entity share price (in usd per share)   $ 34.05                              
EirGen Pharma Limited                                  
Business Acquisition [Line Items]                                  
Total purchase price     $ 133,800                            
Net income (loss)                           1,400      
Value of replacement stock options awards to holders of Bio-Reference stock options     33,600                            
Goodwill     $ 83,373                            
Revenues                           $ 13,500      
Useful life     15 years                            
Cash payment to acquire business     $ 100,200                            
EirGen Pharma Limited | Common Stock                                  
Business Acquisition [Line Items]                                  
Common stock received, in shares (in shares)     2,420,487                            
Trade names | Bio-Reference Laboratories, Inc.                                  
Business Acquisition [Line Items]                                  
Useful life                             5 years    
Customer relationships | Bio-Reference Laboratories, Inc.                                  
Business Acquisition [Line Items]                                  
Measurement period adjustment, Intangible assets                             $ (5,400)    
Customer relationships | EirGen Pharma Limited                                  
Business Acquisition [Line Items]                                  
Useful life     15 years 9 months 18 days                            
Currently Marketed Products | EirGen Pharma Limited                                  
Business Acquisition [Line Items]                                  
Useful life     10 years                            
Other intangible assets | Bio-Reference Laboratories, Inc.                                  
Business Acquisition [Line Items]                                  
Measurement period adjustment, Intangible assets                             $ 7,800    
Maximum | Trade names                                  
Business Acquisition [Line Items]                                  
Useful life                             5 years    
Maximum | Customer relationships                                  
Business Acquisition [Line Items]                                  
Useful life                             20 years    
Maximum | Customer relationships | Bio-Reference Laboratories, Inc.                                  
Business Acquisition [Line Items]                                  
Useful life                             19 years 3 months 18 days    
Maximum | Other intangible assets                                  
Business Acquisition [Line Items]                                  
Useful life                             10 years    
Maximum | Technology | Bio-Reference Laboratories, Inc.                                  
Business Acquisition [Line Items]                                  
Useful life                             10 years 2 months 12 days    
Change in Income Tax Accounting Method                                  
Business Acquisition [Line Items]                                  
Tax benefit                             $ 51,700    
Prepaid Expenses and Other Current Assets | Change in Income Tax Accounting Method                                  
Business Acquisition [Line Items]                                  
Tax benefit                             39,400    
Goodwill         $ (51,700)                   (51,700)    
Deferred Tax Liabilities | Change in Income Tax Accounting Method                                  
Business Acquisition [Line Items]                                  
Tax benefit                             $ 12,300